Introduction
Hypertensive disorders of pregnancy are associated with approximately 5-8% of all complicated pregnancies and probably account for more than 50 000 maternal deaths worldwide each year. 1 In India, hypertensive disorders contribute to 31% of maternal deaths, out of which 24.7% were due to eclampsia. During pregnancy, these disorders are classified into five categories, as recommended by the National High Blood Pressure Education Program Working Group, 1990 (ref. 2) on high blood pressure in pregnancy: (1) gestational hypertension (GH) (2) pre-eclampsia (PE) (3) eclampsia (4) PE superimposed on chronic hypertension and (5) chronic hypertension. Pregnancy-induced hypertensive (PIH) disorders are the syndrome, diagnosed by the presence of hypertension, proteinuria and/or seizures and is thought to be due to endothelial dysfunction. 3 Clinical onset of hypertensive disorders usually occurs in the third trimester of pregnancy. It is thought that systemic inflammatory response and dysfunction of maternal endothelial cells represent the pathological scheme of PIH disorders. 4, 5 Vascular endothelial growth factor (VEGF) is a dimeric glycoprotein with potent angiogenic properties and promotes endothelial cell proliferation, migration and survival. It exerts its biological effects through two high-affinity tyrosine kinase receptors that is, VEGF receptor-1 (VEGFR-1 or flt-1 or fms-like tyrosine kinase-1) and VEGFR-2 (KDR or kinase insert domain-containing receptor or flk-1or fetal liver kinase-1). Of the two receptors, VEGFR-2, nevertheless, has a more important functional role in mediating signaling events involved in endothelial cell mitogenesis, migration, survival and vascular permeability. 6, 7 VEGFR-2 has the two isoforms: a membranous isoform and a soluble isoform.
The latter is generated by a splice variant of VEGFR-2 gene and contains an extracellular-binding domain, lacking signaling tyrosine kinase domain. This soluble form of VEGFR-2 (sVEGFR-2) has been detected in human plasma; however, its functional significance in human health and diseases is still unknown. It remains to be elucidated whether the soluble form of VEGFR-2 may be the result of alternative messenger RNA splicing/or proteolytic cleavage of the membrane-bound receptor/or by some other mechanisms. 6 Under experimental conditions, this protein can bind to VEGF 6 and the recombinant form of this protein has anti-angiogenic activity. 8 The effect of blockage of VEGF action on the pathophysiology of PIH has been suggested recently by several studies in both animals and humans. Gene deletion studies have shown that embryonic mice unable to produce VEGF or deficient in VEGF receptors, fail to develop a normal vasculature and abort.
9,10 Administration of anti-VEGF compounds can induce hypertension and proteinuria in non-pregnant animals 11 and in humans enrolled in anti-angiogenic trial. 12 Hence, besides neovascularization, VEGF maintains blood pressure and is crucial in the formation and maintenance of the glomerular filtration barrier. [13] [14] [15] Therefore, its alteration could well explain the main clinical manifestations of PIH (hypertension, proteinuria and edema).
Various other evidences suggest that the balance between VEGF and their receptors are important for effective placental vasculature during pregnancy. However, till now, only controversial data are available with regard to gestational VEGF concentration in early and late onset of PIH patients. Several authors showed increased VEGF levels, 16, 17 whereas others reported decreased VEGF levels in PE as compared with normal pregnant women. 18 There are clinical studies on sVEGFR-2 as a surrogate biomarker for PE patients. 19 However, no clear pattern has yet emerged to show the clinical utility of circulating sVEGFR-2 in relation to pregnancies complicated by hypertensive disorders and the underlying mechanisms governing the observed changes. Hence, there is a paucity of information on serum VEGF and sVEGFR-2 concentrations in control pregnancy at both gestations (p34 weeks and 434 weeks), and their relationship with various sub-groups of hypertensive disorders during pregnancy particularly in GH and eclampsia. Previously, we have reported increased levels of sVEGFR-1 in PE patients. 20 Therefore, in this study an attempt has been made to appraise the concentration of VEGF and sVEGFR-2 in hypertensive disorders of different clinical severity (GH, PE and eclampsia) in Indian population, to clarify the spectrum of the disease during early and late gestational weeks. This may envisage the association of VEGF and its receptor in patho-physiology of disease.
Materials and methods

Study population
Out of 3700, 540 subjects were volunteered for this cross-sectional study, and were recruited from the OPD (out patient department) clinic between April 2006 and October 2006 from the department of Obstetrics and Gynecology, Safdarjang Hospital, which is a tertiary care hospital of New Delhi. Informed written consent was obtained from each subject enrolled in the study, and the protocol for this study was approved by the Research and Ethics Committee of Vardhman Mahavir Medical College and Safdarjang Hospital. Assuming the prevalence of hypertensive disorders in Delhi the sample size of the present study was found to be adequate to give a power of 80%. All subjects were divided into four groups-control, gestational hypertensive (GH), pre-eclamptic (PE) and eclamptic group. The healthy pregnant women with uncomplicated pregnancies without any history of chronic medical illness, served as control group. (GH) was defined as diastolic blood pressure above 90 mm Hg and systolic blood pressure above 140 mm Hg in normotensive patients after 20 weeks of gestation. PE was defined as diastolic blood pressure above 90 mm Hg and systolic blood pressure above 140 mm Hg in at least two consecutive measurements, 6 h apart, edema and proteinuria X300 mg in a 24-h urine collection or X1 þ dipstick on a random urine sample. In addition, subjects exhibiting PE symptoms along with seizures were classified as eclampsia. None of the patients with GH, PE and Eclampsia had any prior history of hypertension or renal disease. All the subjects were classified and numbered subsequently before any laboratory analysis to avoid bias in the results. A total of 540 serum samples were collected, out of which 90 were from GH, 180 from PE, 90 from eclamptic and 180 were from uncomplicated pregnant control group. The study and control groups were gestationally matched and were further sub-classified as either p34 weeks or 434 weeks. 21 All blood samples from the study groups were collected after the manifestation of clinical symptoms during pregnancy. None of these subjects received any medication before blood sampling. Serum was separated by centrifugation at 1200 r.p.m. for 15 min and stored at À80 1C till the batch analyzed.
Study procedures
Serum levels of VEGF and sVEGFR-2 were quantified by enzyme-linked immunosorbent assay (Quantikine human VEGF and soluble VEGFR-2 R & D Systems Europe, Ltd, United Kingdom), according to manufacturer's instructions. All the serum samples for sVEGFR-2 were diluted as 1:5, respectively, in order to avoid clustering of results and to fall within the measurable range of the kits. The optical density was determined by subtracting readings at 540 nm from the reading at 450 nm. The protein levels were calculated using a standard curve derived from a known concentration of respective recombinant proteins. All assays were performed in duplicate. The minimum detection dose of VEGF and sVEGFR-2 assays were less than 9.0 and 1.0-11.4 pg ml À1 , respectively. The inter-and intra-assay coefficients of variation of VEGF and sVEGFR-2 were 5.4 and 7.3 and 6.5 and 3.5%, respectively.
Statistical analysis
Statistical analysis was performed using statistical software STATA 9.0 (College station, TX, USA). Data were presented as number (%), mean ± s.d. or median (range) as per the requirement. The difference in means/median between the groups was compared using one way analysis of variance/ Mann-Whitney test with Bonferonni corrections. The receiver operating characteristic curve (ROC) analysis was performed to identify the cut-off value of serum levels for study groups in comparison to normal subjects. The P-value o0.05 was considered statistically significant.
Results
There were no significant differences in maternal age and gestational age (weeks of delivery) between control group and in all the hypertensive groups. The primi-gravidae women in p34 and 434 weeks were found to be 47.5 and 55% in control group, 56.6 and 50% in GH group, 55 and 61.6% in PE group and 48.3 and 58.6% in eclamptic group. The difference in mean systolic blood pressure and diastolic blood pressure was statistically significant among all the study groups than the control group. At p34 weeks, newborn weight was found to be significantly reduced in eclampsia group at (P ¼ 0.0001) as compared with PE group. However, at 434 weeks, it was found to be significantly decreased in GH, PE and eclampsia groups-(P ¼ 0.0001, 0.0001 and 0.0001) as compared with the control group (Table 1) .
Mann-Whitney test and ROC analysis
The total serum VEGF and sVEGFR-2 concentrations in uncomplicated control group were 18.0 and 7417.67 pg ml À1 (median), GH group were 18.0 and 5196.84 pg ml À1 (median), PE group were 19.53 and 4427.08 pg ml À1 (median) and eclamptic group were 60.36 and 3972.3 pg ml À1 (median), respectively. There was no change in the serum VEGF levels of early (p34 weeks) GH (median ¼ 18 pg ml À1 ) and PE groups (median ¼ 18 pg ml À1 ) as compared with the control ones (median ¼ 18 pg ml À1 ); however, in early eclamptic group, these levels were found to be upregulated significantly (median ¼ 60.36 pg ml
À1
) as compared with controls (P ¼ 0.0001, Figure 1a ). Among late study groups (434 weeks), these VEGF Table 1 Maternal characteristics: control and study groups Figure 1a , Supplementary Table S1), along with their respective early study groups. Therefore, the positive association was noticed among the serum concentrations of VEGF in GH, PE and eclampsia groups as the gestation advances.
The serum sVEGFR-2 was found to be significantly decreased in early and late GH (median ¼ 5522, 3972 pg ml À1 , P ¼ 0.0001, P ¼ 0.0001), PE (median ¼ 5161, 4088 pg ml À1 , P ¼ 0.0001, P ¼ 0.0001) and eclamptic (median ¼ 3972, 3972 pg ml
, P ¼ 0.0001, P ¼ 0.0001) groups as compared with their respective control groups. Therefore, there was an inverse association among the serum concentrations of sVEGFR-2 in control, GH, PE and eclampsia groups as the gestation advances (Figure 1b , Supplementary  Table S1 ).
It was also observed that sVEGFR-2 concentrations were found to be significantly upregulated at late gestational age group (434 weeks) in the control and all study groups, as compared with their respective early gestational age's group (p34 weeks, Figures 1a and b) .
According to the ROC curve analysis, the serum VEGF and sVEGFR-2 levels in early onset (p34weeks) of GH, PE and eclampsia had the sensitivity of 30 (Figures 2a-h) . The highest positive likelihood ratio of the serum VEGF and sVEGFR-2 levels in GH, PE and eclampsia patients at p34 weeks were 3.0, 4.1, 8.1; 1.0, 1.7 and 1.9 and at 434 weeks were 22, 20.5, 24; 3.2, 9.0 and 9.0, respectively ( Table 2) .
Discussion
VEGF is an endothelial cell-specific growth factor that induces endothelial proliferation and chemotaxis and stimulates new blood vessel formation during fetal development. Besides angiogenesis, VEGF is believed to increase microvascular permeability and also promote coagulation in PIH disorders. 22 Several studies have demonstrated significantly elevated circulating VEGF concentration in women with PE; 23 however; recent studies have demonstrated decreased biologically active free VEGF concentrations in women with PE. 24 In this study, we observed that there was no change in VEGF levels in the complete control group, early weeks of GH and PE group, but these free VEGF levels were significantly elevated in late GH (P ¼ 0.0001), late PE (P ¼ 0.0001) and early (P ¼ 0.0001) and late (P ¼ 0.0001) eclampsia pregnant groups as compared with the control group, suggesting altered VEGF concentrations according to severity of these disorders. These findings support the hypothesis that placental hypoxia is involved in VEGF overproduction in pregnancyassociated hypertensive disorders. 25 It was recently recognized that hypoxia-inducible factor-1a is a key mediator of the hypoxic responses. Hypoxia induces binding of hypoxia-inducible factor-1a to the hypoxia responsive element in the VEGF gene promoter region, which in turn increases transcription of VEGF. 26 Hence, during placental hypoxia, these alterations in the transcription of VEGF may be associated with increased VEGF concentrations in the serum of PIH patients (GH, PE and eclampsia).
The natural soluble form of VEGFR-2 has recently been detected in both mouse and human plasma. of sVEGFR-2 as a potential surrogate biomarker of disease progression in various malignancies, based on the hypothesis that circulating sVEGFR-2 levels may provide insight into VEGFR-2 expression and activation, a critical process in tumor angiogenesis. 27 However, there is a lack of data available examining the relationship between sVEGFR-2 and progression of hypertensive disorders or the underlying factors governing in vivo modulation. Masuyama et al. (2006) 28 noticed that there was no significant difference in the mean serum concentration of sVEGFR-2 between patients with PE and women with normal pregnancies. However, Chaiworapongsa et al. (2008) (ref. 19) reported the association of PE with lower plasma concentrations of sVEGFR-2. The mean serum concentration of sVEGFR-2 in the umbilical vein was reported to be lower in patients with PE than in women with normal pregnancies. 29 Inspite of all above, till date, no study has described the time period of altered sVEGFR-2 concentrations at different intervals of third trimester of GH, PE and eclamptic pregnancy. Our findings are partially consistent with the study conducted by Chaiworapongsa et al. (2008), (ref. 19) which showed that patient with early (p34 weeks) and late onset (434 weeks) PE group had a much lower median serum sVEGFR-2 concentration as compared with their respective controls. In this cross-sectional study, we extend their observation by determining sVEGFR-2 concentration at the early (p34 weeks) and late (434 weeks) onset of different clinical severity of hypertensive disorders, and noticed that these levels were significantly reduced in early onset (p34 weeks, P ¼ 0.0001, P ¼ 0.0001, P ¼ 0.0001) and late onset (434 weeks, P ¼ 0.0001, P ¼ 0.0001, P ¼ 0.0001) of GH, PE and eclampsia groups as compared with their respective controls. These results suggest that the decrease of sVEGFR-2 levels is inversely proportional to the progression of clinical severity of hypertensive disorders (GHeclampsia), during pregnancy indicating its potential role in the pathogenesis of these disorders. Although it was previously shown that sVEGFR-2 can bind to VEGF, 6 it remains unknown whether sVEGFR-2, like other soluble receptors such as sVEGFR-1 30 can bind and sequester VEGF in vivo, thereby influencing binding and activation of VEGFR-1. Ebos et al. (2008) (ref. 31) showed that VEGF-mediated VEGFR-2 downregulation from the cell surface, leads to reduced sVEGFR-2 levels in conditioned media from endothelial cells of tumor, showing that the expression level of VEGFR-2 and its soluble form is linked together. Our results also support that sVEGFR-2 levels reduction may be induced by VEGF-mediated receptor downregulation in hypertensive disorders, and suggest that sVEGFR-2 may serve as an indicator of VEGFinduced VEGFR-2 receptor downregulation. Hence, in this study, reduced levels of sVEGFR-2 in hypertensive disorders may serve as an indicator of their respective cell surface receptors. This decreased VEGFR-2 receptor on cell surface may be due to the increased availability of cell surface VEGFR-1 receptor, which modulates VEGFR-2 due to its VEGF-trapping ability. 32 Hence, serum sVEGFR-2 could be a surrogate marker of endothelial cell function in the maternal circulation, as VEGF signaling through VEGFR-2 is essential for endothelial cell function and survival. 33 The lower sVEGFR-2 plasma concentrations in patients with PE might reflect low regenerative capacity of endothelial cells. 34 It may be due to lower number of circulating endothelial progenitor cells, which have been proposed to reflect the regenerative capacity of endothelial cells. 35 Consistent with this hypothesis, several lines of evidence suggest that patient with hypertensive disorders, especially in the early onset group have an increased risk of developing cardiovascular disease. 36 Hence, these patients were more susceptible to low regenerative capacity for endothelial cells, and thus, might be at risk for cardiovascular disease.
The information regarding the signaling cascades induced by VEGF and its receptor is limited. During normal pregnancy, the production of a soluble VEGFR-1 that antagonizes VEGF signaling, 37 is perhaps a protective response by the placenta to consume the excess serum VEGF levels circulating in the maternal blood. 25 Continuous low levels of VEGF are required for endothelial cells to survive for prolonged periods and function properly. 38 The activation of the VEGFR-2 receptor by VEGF in cells devoid of VEGFR-1 results in a mitogenic response, cell migration and cell proliferation, whereas the activation of VEGFR-1 by VEGF in cells lacking VEGFR-2 induce cell migration but does not induce cell proliferation. 39, 40 These results show that the signal transduction cascades induced by VEGFR-2 are somewhat different. 43 ) reported that hypoxia-induced transcription of VEGF messenger RNA occurs by the binding of hypoxia-inducible factor 1 to an hypoxia-inducible factor-1-binding site located at the VEGF promoter. These alterations in the transcription of VEGF may be associated with increased VEGF levels, resulting in pathological vasculogenesis and angiogenesis in PIH sub-groups (GH, PE and eclampsia). In sVEGFR-2, this hypoxia-induced change in expression levels may be triggered directly or indirectly, as VEGF downregulates the expression of VEGFR-2 through paracrine regulation [44] [45] [46] and sVEGFR-2 may serve as an indicator of VEGF-induced VEGFR-2 receptor downregulation. This may also lead to altered signal transduction pathways of the VEGF family in hypertensive disorders. Salahuddin et al. (2007) (ref. 47 ) observed the diagnostic utility of sFlt-1 in differentiating GH and PE from other hypertensive diseases of pregnancy by ROC curve analysis. In this study, the ROC curve analysis of serum sVEGFR-2 showed a significantly better test to differentiate the late onset (434 weeks) with an early onset (p34 weeks) of GH, PE and eclampsia patients from their respective controls. Hence, our findings suggest the potential diagnostic utility of sVEGFR-2 as sensitive and specific marker in early and late onset of the diseases. To the best of our knowledge, this study was the first to be carried out in different sub-groups of hypertensive disorders with various degrees of clinical severity across the Indian population.
In conclusion, our results revealed that the significant upregulation of VEGF and downregulation of serum sVEGFR-2 levels are directly associated with the clinical severity of disease, as the severity increases from GH to eclampsia in early and late onset of the disease. It is hypothesized that these molecular alterations in VEGF and its receptors may be due to the development of hypoxia in pregnancies complicated by PIH disorders. This study may be used in understanding of the etiopathogenesis of the different types of hypertensive disorders during pregnancy, and may lead to better insights into enhanced diagnosis, treatment and prevention of severity of life-threatening hypertensive disorders.
